J Clin Neurol.  2018 Jul;14(3):413-414. 10.3988/jcn.2018.14.3.413.

A Psychiatric Side Effect of Levetiracetam Can Mimic a Relapse of Anti-Leucine-Rich Glioma Inactivated 1 Encephalitis

• Jang Y
• Lee ST
• Chu K
• Lee SK

• KMID: 2415061
• DOI: http://doi.org/10.3988/jcn.2018.14.3.413

Abstract

No abstract available.

MeSH Terms

Encephalitis*
Glioma*
Recurrence*

Figure

• 

  Fig. 1 Timeline of the patient with anti-LGI1 encephalitis who exhibited psychiatric side effects of levetiracetam. New psychiatric symptoms appeared at 6 months after starting levetiracetam. The negative result of the anti-LGI1 Ab test in the serum confirmed that there was no relapse of anti-LGI1 encephalitis. The psychiatric symptoms disappeared dramatically after stopping levetiracetam. anti-LGI1 Ab: anti-leucine-rich glioma inactivated 1 antibody, FBDS: faciobrachial seizure, IVIG: intravenous immunoglobulin, SNUH: Seoul National University Hospital.

Reference

1. Pickrell WO, Lacey AS, Thomas RH, Lyons RA, Smith PE, Rees MI. Trends in the first antiepileptic drug prescribed for epilepsy between 2000 and 2010. Seizure. 2014; 23:77–80.

2. Liu X, Carney PR, Bussing R, Segal R, Cottler LB, Winterstein AG. Trends in antiepileptic drug use in children and adolescents with epilepsy. Pediatr Neurol. 2017; 74:32–40.

3. Harden C. Safety profile of levetiracetam. Epilepsia. 2001; 42:Suppl 4. 36–39.

4. Mula M, Trimble MR, Yuen A, Liu RS, Sander JW. Psychiatric adverse events during levetiracetam therapy. Neurology. 2003; 61:704–706.